The DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index.
Thiazolidinediones: the Forgotten Diabetes Medications
Open accessAbstract
Purpose of Review: Thiazolidinediones (TZDs) are the only pharmacologic agents that specifically treat insulin resistance. The beneficial effects of TZDs on the cardiovascular risk factors associated with insulin resistance have been well documented. TZD use has been limited because of concern about safety issues and side effects. Recent Findings: Recent studies indicate that cardiovascular toxicity with rosiglitazone and increase in bladder cancer with pioglitazone are no longer significant issues. There are new data which show that pioglitazone treatment reduces myocardial infarctions and ischemic strokes. New data concerning TZD-mediated edema, congestive heart failure, and bone fractures improves the clinician’s ability to select patients that will have minimal significant side effects. Summary: Thiazolidinediones are now generic and less costly than pharmaceutical company–promoted therapies. Better understanding of the side effects coupled with clear benefits on the components of the insulin resistance syndrome should promote TZD use in treating patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, pioglitazone lowers myocardial infarctions (MI) and ischemic strokes, according to recent findings.”
From A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents. (2024) · cites this paper as [67]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are no pharmacologic treatments that particularly treat insulin resistance other than TZDs.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Macrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
Ford, E. S. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1769 · Cited by 1,718
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Research works printed but not linked: 2
- Lebovitz HE. In: Wass JAH, Stewart PM, editors. The metabolic syndrome chapter 13.36 in Oxford textbook of endocrinology and diabetes 2nd Edition. Oxford: OXFORD University Press; 2011.
- Gervois P, Fruchart J-C, Staels B. Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab. 2007;3:145–55. · DOI
Cited by
Sorted by citations
Type II diabetes mellitus: a review on recent drug based therapeutics.
Padhi, S., Nayak, A. K., & Behera, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110708 · Cited by 726
Fleishman, J. S., & Kumar, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01811-6 · Cited by 615
Bioactive compounds in anti-diabetic plants: from herbal medicine to modern drug discovery
Tran, N., Pham, B., & Le, L. (2020) · Biology · doi:10.3390/biology9090252 · Cited by 553
Lipid metabolism in sickness and in health: Emerging regulators of lipotoxicity
Yoon, H., Shaw, J. L., Haigis, M. C., & Greka, A. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.08.027 · Cited by 538
ACSL4 deficiency confers protection against ferroptosis-mediated acute kidney injury
Wang, Y., Zhang, M., Bi, R., Su, Y., Quan, F., Lin, Y., Yue, C., Cui, X., Zhao, Q., Liu, S., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102262 · Cited by 444
Insulin resistance and cardiovascular disease
Kosmas, C. E., Bousvarou, M. D., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E. (2023) · Journal of International Medical Research · doi:10.1177/03000605231164548 · Cited by 434
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 315
Dahlén, A. D., Dashi, G., Maslov, I. O., Attwood, M. M., Jonsson, J., Trukhan, V., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.807548 · Cited by 308
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146353 · Cited by 256
Mantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00261-2 · Cited by 230
Xia, T., Liu, C., Hu, Y., Luo, Z., Chen, F., Yuan, L., & Tan, X. (2021) · Food Research International · doi:10.1016/j.foodres.2021.110717 · Cited by 162
Pharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 173
COVID-19 and diabetes: The why, the what and the how
Cuschieri, S., & Grech, S. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107637 · Cited by 153
Insulin resistance in ischemic stroke: Mechanisms and therapeutic approaches
Ding, P.-F., Zhang, H., Wang, J., Gao, Y., Mao, J.-N., Hang, C., & Li, W. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1092431 · Cited by 143
Youth-onset type 2 diabetes mellitus: an urgent challenge
Bjornstad, P., Chao, L. C., Cree‐Green, M., Dart, A. B., King, M., Looker, H. C., Magliano, D. J., Nadeau, K. J., Pinhas‐Hamiel, O., SHAH, A. S., et al. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00645-1 · Cited by 146
Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
Kim, H.-M., Lee, D. S., An, T. H., Park, H., Kim, W. K., Bae, K., & Oh, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094495 · Cited by 133
Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug
Nesti, L., Tricò, D., Mengozzi, A., & Natali, A. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01294-7 · Cited by 126
Liu, Y. F., Chen, J., Liang, H., Cai, Y., Li, X., Li, Y., Zhou, L., Shan, L., & Wang, H. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02927-8 · Cited by 123
Inflammatory Mechanisms of Diabetes and Its Vascular Complications
Nedosugova, L. V., Markina, Y. V., Бочкарева, Л. А., Кузина, И. А., Petunina, N. A., Yudina, I. Y., & Kirichenko, T. V. (2022) · Biomedicines · doi:10.3390/biomedicines10051168 · Cited by 135
Zhao, H., Xing, C., Zhang, J., & He, B. (2021) · Reproductive Health · doi:10.1186/s12978-021-01207-7 · Cited by 129
The Metabolic Basis of Immune Dysfunction Following Sepsis and Trauma
McBride, M. A., Owen, A. M., Stothers, C. L., Hernandez, A., Luan, L., Burelbach, K. R., Patil, T. K., Bohannon, J. K., Sherwood, E. R., & Patil, N. K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01043 · Cited by 120
The Mitochondrial Ca2+ Uptake and the Fine-Tuning of Aerobic Metabolism
Gherardi, G., Monticelli, H., Rizzuto, R., & Mammucari, C. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.554904 · Cited by 109
Plant Extracts for Type 2 Diabetes: From Traditional Medicine to Modern Drug Discovery
Lee, J., Noh, S., Lim, S., & Kim, B. (2021) · Antioxidants · doi:10.3390/antiox10010081 · Cited by 122
Kung, Y.-A., Chiang, H.-J., Li, M.-L., Gong, Y.-N., Chiu, H.-P., Hung, C.-T., Huang, P.-N., Huang, S.-Y., Wang, P.-Y., Hsu, T.-A., et al. (2022) · mBio · doi:10.1128/mbio.02717-21 · Cited by 107
Massimino, E., Izzo, A. C., Riccardi, G., & Pepa, G. D. (2021) · Cells · doi:10.3390/cells10081958 · Cited by 108
The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD
Hong, T., Chen, Y., Li, X., & Lü, Y. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6889533 · Cited by 110
Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era?
Katsiki, N., & Ferrannini, E. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107723 · Cited by 91
Piragine, E., Petri, D., Martelli, A., Calderone, V., & Lucenteforte, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051981 · Cited by 113
Management of diabesity: Current concepts
Michaelidou, M., Pappachan, J. M., & Jeeyavudeen, M. S. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i4.396 · Cited by 97
Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?
Carboni, E., Carta, A. R., & Carboni, E. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109776 · Cited by 89
Olatunde, A., Nigam, M., SINGH, R. K., Panwar, A. S., Lasisi, A., Alhumaydhi, F. A., Kumar, V., Mishra, A. P., & Sharifi‐Rad, J. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02202-5 · Cited by 94
Vetrano, E., Rinaldi, L., Mormone, A., Giorgione, C., Galiero, R., Caturano, A., Nevola, R., Marfella, R., & Sasso, F. C. (2023) · Biomedicines · doi:10.3390/biomedicines11020468 · Cited by 94
Type 2 diabetes mellitus – conventional therapies and future perspectives in innovative treatment
Gieroba, B., Kryska, A., & Sroka‐Bartnicka, A. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102037 · Cited by 116
4-Thiazolidinone-Bearing Hybrid Molecules in Anticancer Drug Design
Roszczenko, P., Holota, S. M., Szewczyk-Roszczenko, O. K., Dudchak, R., Bielawski, K., Bielawska, A., & Lesyk, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113135 · Cited by 79
Francque, S., Bédossa, P., Abdelmalek, M. F., Anstee, Q. M., Bugianesi, E., Ratziu, V., Huot-Marchand, P., Bruno, S., Junien, J., Broqua, P., et al. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106170 · Cited by 78
Zhang, Z., Zhang, X., Meng, L., Gong, M., Li, J., Shi, W., Qiu, J., Yang, Y., Zhao, J., Suo, Y., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.658362 · Cited by 79
Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches
Radosavljević, T. S., Branković, M., Samardžić, J., Djuretić, J., Vukićević, D., Vučević, D. B., & Jakovljevic, V. L. (2024) · Antioxidants · doi:10.3390/antiox13080906 · Cited by 88
Alrouji, M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alexiou, A. T., Papadakis, M., Saad, . M., & Batiha, G. E. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01082-1 · Cited by 81
Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
Bae, J., Park, T., Kim, H., Lee, M., & Soo, B. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0272 · Cited by 79
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Genua, I., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0012 · Cited by 74
Diabetes and Impaired Fracture Healing: A Narrative Review of Recent Literature
Tanios, M., Brickman, B., Cage, E., Abbas, K.-A. J., Smith, C. J., Atallah, M., Baroi, S., & Lecka‐Czernik, B. (2022) · Current Osteoporosis Reports · doi:10.1007/s11914-022-00740-z · Cited by 73
Kamata, S., Honda, A., & Ishii, I. (2023) · Biomolecules · doi:10.3390/biom13081264 · Cited by 71
The Effects of Major Mushroom Bioactive Compounds on Mechanisms That Control Blood Glucose Level
Јovanović, J. A., Mihailović, M., Uskoković, A. S., Grdović, N., Dinić, S., & Vidaković, M. (2021) · Journal of Fungi · doi:10.3390/jof7010058 · Cited by 72
Tegegne, B. A., Adugna, A., Yenet, A., Yihunie Belay, W., Yibeltal, Y., Dagne, A., Hibstu Teffera, Z., Amare, G. A., Abebaw, D., Tewabe, H., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1440456 · Cited by 61
“The capacity of clinicians to choose patients who would experience few to no major side effects is enhanced by new information regarding TZDs-mediated congestive heart failure, bone fractures, and edema (67).”
BackgroundSeaweed Derived Lipids Are a Potential Anti-Inflammatory Agent: A Review
Jaworowska, A., & Murtaza, A. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20010730 · Cited by 67
AMPK Activity: A Primary Target for Diabetes Prevention with Therapeutic Phytochemicals
Chung, M., Choi, H., & Hwang, J. (2021) · Nutrients · doi:10.3390/nu13114050 · Cited by 66
Chaouiki, A., Chafiq, M., Ko, Y. G., Al‐Moubaraki, A. H., Thari, F. Z., Salghi, R., Karrouchi, K., Bougrin, K., Ali, I. H., & Lgaz, H. (2022) · Metals · doi:10.3390/met12101598 · Cited by 59
The management of diabetes mellitus by mangiferin: advances and prospects
Wang, M., Liang, Y., Chen, K., Wang, M., Long, X., Liu, H., Sun, Y., & He, B. (2022) · Nanoscale · doi:10.1039/d1nr06690k · Cited by 56
Old age as a risk factor for liver diseases: Modern therapeutic approaches
Georgieva, M., Xenodochidis, C., & Krasteva, N. A. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112334 · Cited by 60
Xia, T., He, W., Luo, Z., Wang, K., & Tan, X. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132256 · Cited by 54
Ng, C. H., Lin, S. Y., Chin, Y. H., Lee, M. H., Syn, N. L. X., Goh, X. L., Koh, J. H., Quek, J., Tan, D. J. H., Mok, S. F., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.09.013 · Cited by 52
Sobolev, V. V., Tchepourina, E., Korsunskaya, I. M., Geppe, N. A., Chebysheva, S. N., Soboleva, A. G., & Mezentsev, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179708 · Cited by 56
Sharma, V., & Patial, V. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.991059 · Cited by 50
Fan, X., Jiao, G., Pang, T., Wen, T., He, Z., Han, J., Zhang, F., & Chen, W. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154740 · Cited by 50
Sharma, A., Mah, M., Ritchie, R. H., & Blasio, M. J. D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108008 · Cited by 52
Souza-Tavares, H., Miranda, C. S., Vasques‐Monteiro, I. M. L., Sandoval, C., Santana-Oliveira, D. A., Silva-Veiga, F. M., Fernandes‐da‐Silva, A., & Souza‐Mello, V. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i26.4136 · Cited by 51
Targeting Adiponectin in Breast Cancer
Nehme, R., Diab‐Assaf, M., Decombat, C., Delort, L., & Caldefie‐Chezet, F. (2022) · Biomedicines · doi:10.3390/biomedicines10112958 · Cited by 47
GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice
Quarta, C., Stemmer, K., Novikoff, A., Yang, B. S., Klingelhuber, F., Harger, A., Bakhti, M., Bastidas-Ponce, A., Baugé, E., Campbell, J. E., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00617-6 · Cited by 47
The physiology of MASLD: molecular pathways between liver and adipose tissues
Lee, W., Kipp, Z. A., Bates, E. A., Pauss, S. N., Martinez, G. J., & Hinds, T. D. (2025) · Clinical Science · doi:10.1042/cs20257571 · Cited by 52
Zhou, Y., Suo, W., Zhang, X., Liang, J., Zhao, W., Wang, Y., Li, H., & Ni, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115669 · Cited by 43
Cannabidiol ameliorates mitochondrial disease via PPARγ activation in preclinical models
Puighermanal, E., Luna‐Sánchez, M., Gella, A., van der Walt, G., Urpi, A., Royo, M., Tena‐Morraja, P., Appiah, I., de Donato, M. H., Ménardy, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51884-8 · Cited by 41
Zhu, B., Wei, X., Narasimhan, H., Qian, W. G., Zhang, R., Cheon, I. S., Wu, Y., Li, C., Jones, R. G., Kaplan, M. H., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adf0348 · Cited by 39
Zisis, M., Chondrogianni, M. E., Ανδρουτσάκος, Θ., Rantos, I., Oikonomou, E. K., Chatzigeorgiou, A., & Kassi, E. N. (2025) · Biomolecules · doi:10.3390/biom15030324 · Cited by 44
The forgotten type 2 diabetes mellitus medicine: rosiglitazone
Xu, B., Xing, A., & Li, S. (2021) · Diabetology International · doi:10.1007/s13340-021-00519-0 · Cited by 38
Szałabska-Rąpała, K., Borymska, W., & Kaczmarczyk‐Sedlak, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810050 · Cited by 38
Targeting PPARs for therapy of atherosclerosis: A review
Miao, M., Wang, X., Liu, T., Li, Y., Yu, W., Yang, T.-M., & Guo, S. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125008 · Cited by 40
Li, Z., Lin, C., Cai, X., Lv, F., Yang, W., & Ji, L. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01645-y · Cited by 44
Sandoval, C. O., Fabela‐Illescas, H. E., Fernández‐Martínez, E., Ortiz-Rodríguez, M. A., Cariño‐Cortés, R., Ariza‐Ortega, J. A., Hernández-González, J. C., Olivo, D., Valadez-Vega, M. D. C., Belefant‐Miller, H., et al. (2022) · Antioxidants · doi:10.3390/antiox11030553 · Cited by 36
New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment
Haddad, D., Dsouza, V. S., Al‐Mulla, F., & Madhoun, A. S. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010571 · Cited by 35
Kounatidis, D. C., Vallianou, N. G., Rebelos, E., Kouveletsou, M., Kontrafouri, P., Eleftheriadou, I., Diakoumopoulou, E., Karampela, Ι., Tentolouris, N., & Dalamaga, Μ. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00612-4 · Cited by 43
Antidiabetic drugs and oxidized low-density lipoprotein: A review of anti-atherosclerotic mechanisms
Ahmadi, A., Panahi, Y., Johnston, T. P., & Sahebkar, A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105819 · Cited by 36
Perike, N., Edigi, P. K., Gurrapu, N., Thumma, V., Bujji, S., & Subhashini, N. J. P. (2022) · ChemistrySelect · doi:10.1002/slct.202203778 · Cited by 35
Elkomy, N. M. I. M., El-Shaibany, A. M., Elnagar, G. M., Abdelkhalek, A. S., Al-Mahbashi, H. M., Elaasser, M. M., Raweh, S. M., Aldiyarbi, M. A., & Raslan, A. E. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116310 · Cited by 34
Thiazolidinone: A structural motif of great synthetic and biological importance
Aqlan, F. M., Al‐Bogami, A. S., Alqahtani, N. F., Wani, M. Y., & Khan, S. A. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131771 · Cited by 34
Qin, C., Díaz-Gallo, L.-M., Tang, B., Wang, Y., Nguyen, T.-D., Harder, A., Lu, Y., Padyukov, L., Askling, J., & Hägg, S. (2023) · European Journal of Epidemiology · doi:10.1007/s10654-023-01000-9 · Cited by 35
Kajal, K., Singh, G., Pradhan, T., Bhurta, D., & Monga, V. (2022) · Archiv der Pharmazie · doi:10.1002/ardp.202100517 · Cited by 34
Honda, A., Kamata, S., Akahane, M., Machida, Y., Uchii, K., Shiiyama, Y., Habu, Y., Miyawaki, S., Kaneko, C., Oyama, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094726 · Cited by 32
Oduro, P. K., Fang, J., Niu, L., Li, Y., Li, L., Zhao, X., & Wang, Q. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104893 · Cited by 31
Sharifi, Y., Payab, M., Mohammadi‐Vajari, E., Aghili, S. M. M., Sharifi, F., Mehrdad, N., Kashani, E., Shadman, Z., Larijani, B. A., & Ebrahimpur, M. (2021) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-021-00822-2 · Cited by 32
Thiazolidinedione as a Promising Medicinal Scaffold for the Treatment of Type 2 Diabetes
Singh, G., Kumar, R., Desna, D. S., Chaudhary, M., Kaur, C., & Khurana, N. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998254798231005095627 · Cited by 34
González, L. F., Bevilacqua, L. E., & Naves, R. F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122055 · Cited by 31
Kores, K., Konc, J., & Bren, U. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030315 · Cited by 29
A Dichotomous Role for FABP7 in Sleep and Alzheimer’s Disease Pathogenesis: A Hypothesis
Needham, H., Torpey, G., Flores, C. C., Davis, C. J., Vanderheyden, W. M., & Gerstner, J. R. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.798994 · Cited by 29
Lee, W., Kipp, Z. A., Pauss, S. N., Martinez, G. J., Bates, E. A., Badmus, O. O., Stec, D. E., & Hinds, T. D. (2025) · Clinical Science · doi:10.1042/cs20242825 · Cited by 30
Clinical pharmacology of antidiabetic drugs: What can be expected of their use?
Scheen, A. J. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104158 · Cited by 29
Tienda-Vázquez, M. A., Melchor-Martínez, E. M., Elizondo‐Luévano, J. H., Parra‐Saldívar, R., Lara-Ortiz, J. S., Luna-Sosa, B., & Scheckhuber, C. Q. (2023) · Processes · doi:10.3390/pr11051299 · Cited by 28
Pathophysiology and Advances in the Therapy of Cardiomyopathy in Patients with Diabetes Mellitus
Graczyk, P., Dach, A., Dyrka, K., & Pawlik, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25095027 · Cited by 29
Zahr, T., Liu, L., Chan, M., Zhou, Q., Cai, B., He, Y., Aaron, N., Accili, D., Sun, L., & Qiang, L. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318061 · Cited by 26
New Aspects of Diabetes Research and Therapeutic Development
Satin, L. S., Soleimanpour, S. A., & Walker, E. M. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000160 · Cited by 30
Dietary Control of Inflammation and Resolution
Sears, B., & Saha, A. K. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.709435 · Cited by 30
The circadian rhythm: an influential soundtrack in the diabetes story
Hariri, A., Mirian, M., Zarrabi, A., Kohandel, M., Amini-Pozveh, M., Aref, A. R., Tabatabaee, A., Prabhakar, P. K., & Sivakumar, P. M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1156757 · Cited by 30
Hyperglycemia-driven signaling bridges between diabetes and cancer
Ghareghomi, S., Arghavani, P., Mahdavi, M., Khatibi, A., García‐Jiménez, C., & Moosavi‐Movahedi, A. A. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116450 · Cited by 29
Activation of Insulin Signaling by Botanical Products
Rosenzweig, T., & Sampson, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084193 · Cited by 25
Nazreen, S. (2021) · Archiv der Pharmazie · doi:10.1002/ardp.202100021 · Cited by 25
He, Y., Zhang, R., Yu, L., Zahr, T., Li, X., Kim, T., & Qiang, L. (2023) · Cells · doi:10.3390/cells12101424 · Cited by 25
Posttransplant diabetes mellitus: recent developments in pharmacological management of hyperglycemia
Munoz Pena, J. M., & Cusi, K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad395 · Cited by 24
Rocha, S., Corvo, M. L., Freitas, M., & Fernandes, E. G. R. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124441 · Cited by 26
Nicchio, I. G., Cirelli, T., Quil, L. C. D. C., Camilli, Â. C., Scarel‐Caminaga, R. M., & Leite, F. R. M. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116908 · Cited by 28
Przybycień, P., Gąsior‐Perczak, D., & Placha, W. (2022) · Cells · doi:10.3390/cells11162569 · Cited by 26
Zhang, C., Yu, H., Ye, J., Tong, H., Wang, M., & Sun, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316736 · Cited by 26
Metadata
- Authors
- Lebovitz, H. E.
- Affiliations
- SUNY Downstate Health Sciences University (US)
- Corresponding author
- Lebovitz, Harold E.
- Venue
- Current Diabetes Reports
- Published
- 2019-11-27
- Volume
- 19
- Issue
- 12
- Pages
- 151-151
- ISSN
- 1534-4827 (ISSN-L)
- 1539-0829
- PMC
- PMC6881429
- OpenAlex
- W2990309084
- Cited by
- 388
- References
- 85
- Citations by year
- 2026: 45 · 2025: 62 · 2024: 75 · 2023: 68 · 2022: 65 · 2021: 57 · 2020: 16
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Current Diabetes Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- thiazolidinediones, insulin resistance, type 2 diabetes, rosiglitazone, pioglitazone, cardiovascular risk, myocardial infarction, ischemic stroke, bladder cancer, congestive heart failure, edema, bone fractures, drug safety, generic drugs
- MeSH terms
- Rosiglitazone, Pioglitazone, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin Resistance, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
